Botulinum toxin therapy in pain management

Anesthesiology Clinics of North America

Volumn 21, Issue 4, 2003, Pages 715-731

  Raj, P Prithvi ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ANALGESIA; ANTIBODY PRODUCTION; ANTINOCICEPTION; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSPEPSIA; DYSPHAGIA; DYSTONIA; HEADACHE; HUMAN; INJECTION PAIN; MOTOR NEURON DISEASE; MUSCLE SPASM; MYOFASCIAL PAIN; PAIN ASSESSMENT; PRACTICE GUIDELINE; REVIEW; XEROSTOMIA;

EID: 0346102487     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8537(03)00082-8     Document Type: Review

References (86)

1. Van Ermengem E. A new anaerobic bacillus and its relation to botulism. Rev Infect Dis 1979; 1:701-19.
2. Snipe PT, Sommer H. Studied on botulinus toxin 3. Acid precipitation of botulinus toxin. J Infect Dis 1929;43:152-60.
3. Shantz EJ. Historical Perspective. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker Inc.; 1994.
4. Scott AB, Rosenbaum AL, Collins CC. Pharmacologic weakening of extra-ocular muscles. Invest Ophthalmol 1973;12:924-7.
5. Scott AB. Botulinum toxin injection into extra-ocular muscles as an alternative to strabismus surgery. Ophthalmology 1980;87:1044-9.
6. Tsui JKC. Botulinum toxin as a therapeutic agent. Pharmacol Ther 1996;72:13-24.
7. Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker Inc.; 1994.
8. Whelan SM, Elmore MJ, Bodsworth NJ, Brehm JK, Atkinson T, Minlon NP. Molecular cloning of the Closiridium bolulinun structural gene encoding the type B neurotoxin and determination of its cntire nucleotide sequence. Appl Environ Microbiol 1992;58:2345-54.
9. East AK, Richardson FT, Allaway D, Collins MD, Roberts TA, Thompsun DE. Sequence of the gene encoding type F neurotoxin of Closiridium bolulinum. FEMS Microbiol Lett 1992;96: 225-30.
10. DasGupta BR. Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystaline type A toxin. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker Inc.; 1994. p. 15-39.
11. Hesse S, Lucke D, Malezic M, et al. Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychol 1994;57:1321-4.
12. Sellin LC, Thesless S, Dasgupta BR. Different effects of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction. Acta Physiol Scand 1983; 119(2): 127-33.
13. Sellin LC, Kauffman JA, Dasgupta BR. Comparison of the effects of botulinum neurotoxin types A and E at the rat neuromuscular junction. Med Biol 1983;61(2):120-5.
14. Kauffman JA, Way JF, Siegel LS, Sellin LC. Comparison of the action of types A and F botulinum toxin at the rat neuromuscular juntion. Toxicol Appl Pharmacol 1985;79(2): 211-7.
15. Schantz EJ, Johnson EA. Preparation and characterization of botulinum toxin type A for human treatment. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker Inc.; 1994. p. 41-9.
16. Sugiyama H. Clostridium botulinum neurotoxin. Microbiol Rev 1980;44:419-48.
17. Moyor E, Settler PE. Botulinum toxin type B: experimental and clinical experience. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. p. 71-86.
18. Borodic GE, Pearce LB, Smith KL, et al. Botulinum B toxin as an alternative to botulinum A toxin: a histology study. Ophthal Plast Reconstr Surg 1993;9:182-90.
19. Greene P, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 1993;8:479-83.
20. Ludlow CL, Hallett M, Rhew K, et al. Therapeutic use of type F botulinum toxin. NEJM 1992; 326:349-50.
21. DasGupta BR. Structure and biological activity of botulinum neurotoxin. J Physiol (Paris) 1990;84:220-8.
22. Montccucco C. How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem Sci 1986;11:314-7.
23. Evans DM, Williams RS, Shone CC, Hambleton P, Melling J, Dolly JO. Botulinum neurotoxin type B: its purification, radioiodination and interaction with rat-brain synaptosomal membranes. Eur J Biochem 1986;154:409-16.
24. Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 1986;103:521-34.
25. Burgen AS, Dickens VF, Zatman JJ. The action of botulinum toxin on the neuromuscular junction. J Physiol (London) 1949;109:10-24.
26. Sudhof TC. The synaptic vesicle cycle: A cascade of protein-protein interactions. Nature 1995; 375:645-53.
27. Simpson LL. The study of clostridial and related toxins. The search for unique mechanisms and common denominators. J Physiol (Paris) 1990;84:143-51.
28. Poulain B, Tauc L, Maisery EA, et al. Neurotransmitter release is blocked intracellularly by botulinum neurotoxin, and this requires uptake of both toxin polypeptides by a process mediated by the larger chain. Proc Natl Acad Sci USA 1988;85:4090-4.
29. Finkelstein A. Channels formed in phospholipid bilayer membranes by diphtheria, tetanus, botulinum, and anthrax toxin. J Physiol (Paris) 1990;84:188-90.
30. Schiavo G, Boquet P, DasGupta BR, Montecucco C. Membrane interactions of tetanus and botulinum neurotoxins: a photolabelling study with photoactivatable phospholipid. J Physiol (Paris) 1990;84:180-7.
31. Duchen LW, Strich SJ. The effects of botulinum toxin on the pattern of innervation of skeletal muscle in the mouse. Q J Exp Physiol 1968;53:84-9.
32. Elston JS. Botulinum toxin treatment of blepharospasm. In: Fahn S, Marsden CD, editors. Dystonia 2. New York: Raven Press; 1988. p. 579-81.
33. Borodic GE, Ferrante R. Histologic effects of repeated botulinum toxin over many years in human orbicularis oculi muscle. J Clin Neuroophthalmol 1992;12:121-7.
34. Harris CP, Alderson K, Nebeker J, et al. Histology of human orbicularis muscle Treated with botulinum toxin. Arch Ophthalmol 1991;109:393-5.
35. Borodic GE, Ferrante RJ, Pearce LB, Alderson K. Pharmacology and histology of the therapeutic application of botulinum toxin. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekket Inc.; 1994. p. 119-57.
36. Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker Inc.; 1994.
37. Racz GB. Botulinum toxin as a new approach for refractory pain syndromes. Pain Digest 1998;8: 353-6.
38. Porta M, Perretti A, Gamba M, Luccarelli G, Fomari M. The rationale and results of treating muscle spasm and myofascial syndromes with botulinum toxin type A. Pain Digest 1998;8:346-52.
39. Abrams BM. Tutorial 36: Myofascial pain syndrome and fibromyalgia. Pain Digest 1998;8: 264-72.
40. Lang AM. Botulinum toxin for myofascial pain. In: Advancements in the treatment of neuromuscular pain. San Diego: Johns Hopkins University Office of Continuing Medical Education Syllabus; October 1999. p. 23-8 [chapter 5].
41. Simpson LL. Peripheral actions of the botulinum toxins. In: Simpson LL, editor. Botulinum neurotoxin and tetanus toxin. San Diego: Academic Press; 1989. p. 153-78.
42. Chen R, Karp BI, Hallett M. Botulinum toxin type F for treatment of dystonia: long term experience. Neurology 1998;51:1494-6.
43. Fish DR, Sawyers D, Allen PJ, Blackie JD, Lees AJ, Marsden CD. The effect of sleep on the dyskinetic movements of Parkinson's desease, Gilles de la Tourette syndrome, Huntington's disease, and torsion dystonia. Arch Neurol 1991;48:210-4.
44. Poewe W, Wissel J. Experience with botulinum toxin in cervical dystonia. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker Inc.; 1994. p. 267-78.
45. Sheehy MP, Marsden CD. Writer's cramp-focal dystonia. Brain 1982;105:461-80.
46. Hunter D. The diseases of occupations. 6th edition. London: Hodder & Stoughton; 1978.
47. Gowers WR. A manual of diseases of the nervous system. Philadelphia: P. Blakiston Son & Co.; 1888.
48. Albanese A, Bentivoglio AR, Cassetta E, Viggiano A, Maria G, Gui D. Review article: The use of botulinum toxin in the alimentary tract. Aliment Pharmacol Ther 1995;9(6):599-604.
49. Brin MF, Fahn SM, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Discord 1987;2:237-54.
50. Cohen LG, Hallett M, Celler BD, Hochberg F. Treatment of focal dystonia of the hand with botulinum toxin injections. J Neurol Neurosurg Psychiatry 1989;52:355-63.
51. Cole RA, Cohen LG, Hallett M. Treatment of musician's cramp with botulinum toxin. Med Problems Performing Artists 1991;6:137-43.
52. Poungvarin N. Writer's cramp: the experience with botulinum toxin injections in 25 patients. J Med Assoc Thai 1991;74:239-47.
53. Rivest J, Lees AJ, Marsden CD. Writer's cramp: treatment with botulinum toxin injections. Mov Discord 1991;6:55-9.
54. Jankovic J, Schwartz KS. Use of botulinum toxin in the treatment of hand dystonia. J Hand Surg 1993;18A:883-7.
55. Karp BI, Cole RA, Cohen LG, Grill S, Lou J-S, Hallett M. Long-term botulinum toxin treatment of focal hand dystonia. Neurology 1994;44:70-6.
56. Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology 1992;42:627-30.
57. Tsui JKC, Bhatt M, Calne S, Clane DB. Botulinum toxin in the treatment of writer's cramp: a double-blind study. Neurology 1993;43:183-5.
58. Cole R, Hllett M, Cohen LG. Double-blind trial of botulinum toxin for treatment of focal hand dystonia. Move Discord 1995;10:466-71.
59. Young RR. Treatment of spastic paresis. NEJM 1989;320:1553-5.
60. Burke D. Critical examination of the case for or against fusimotor involvement in disorder of muscle tone. In: Desmedt JE, editor. Motor control mechanisms in health and disease. New York: Raven Press; 1983. p. 133-50.
61. Dimitrijevic MR. Spasticity and rigidity. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. 2nd edition. Baltimore: Williams and Wilkins; 1993. p. 443-53.
62. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: A randomized, double-blind, placebo-controlled trial. Neurology 1996;46(5):1306-10.
63. Gordon J. Spinal mechanisms of motor coordination. In: Kandel ER, Schwartz JH, Jessell TM, editors. Principles of neural science. 3rd edition. Norwalk: Appleton & Lange; 1991. p. 581-95.
64. Delwaide PJ, Yoiung RR, editors. Clinical neurophysiology in spasticity. Amsterdam: Elsevier; 1985.
65. Young RR. Physiologic and pharmacologic approaches to spasticity. Neurol Clin 1987;5:529-39.
66. Katz RT. Management of spasticity. Am J Phys Med Rehabil 1988;67:108-16.
67. Gans BM, Glenn MB. Introduction. In: Glenn MB, Whyte J, editors. The practical management of spasticity in children and adults. Philadelphia: Lea & Febiger; 1990. p. 1-7.
68. Mayer NH. Functional management of spasticity after head injury. J Neuro Rehab 1991;5:S1-4.
69. Lehmkuhl LD, Thoi LI, Baize C, Kelley CJ, Krawcryk L, Bontke CF. Multunodality treatment of joint contractures in patients with severe brain injury: cost, effectiveness, and integration of therapies in the application of seria Vinhibitive casta. J Head Trauma Rehabil 1990;5:23-42.
70. Carthidge NE, Hudgson P, Weightman D. A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci 1974;23:17-24.
71. Whyte J, Robinson KM. Pharmacologic management. In: Glenn MB, Whyte J, editors. The practical management of spasticity in children and adults. Philadelphia: Lea & Febiger; 1990. p. 201-26.
72. Chan CH. Dantrolene sodium and hepatic injury. Neurology 1999;40:1427-32.
73. Reeves KD, Baker A. Mixed somatic peripheral nerve block for painful or intractable spasticity: a review of 30 years of use. AJPM 1992;2:205-10.
74. Glenn MB. Nerve blocks. In: Glenn MB, Whyte J, editors. The practical management of spasticity in children and adults. Philadelphia: Lea & Febiger; 1990. p. 227-58.
75. Kasdon KL, Abromovitz JN. Neurosurgical approaches. In: Glenn MB, Whyte J, editors. The practical management of spasticity in children and adults. Philadelphia: Lea & Febiger; 1990. p. 259-67.
76. Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993;270:2476-7.
77. Bowers DN, Averill A. Intrathecal baclofen for Intractable spasticity due to severe traumatic brain injury [abstract]. Arch Phy Med Rehabil 1991;72:816.
78. Meythaler JM. Use of intrathecal baclofen in brain injury patient's abstract. Arch Phys Med Rehabil 1994;75:1036.
79. Shaari CM, Sanders I. Assessment of the bilogical activity of botulinum toxin. In: Jankovic J, Siegal GJ, editors. Therapy with botulinum toxin. New York: Marcel Dekker Inc.; 1994. p. 159-70.
80. Han SC, Harrison P. Myofascial pain syndrome and trigger-point management. Reg Anesth 1995;65:167-70.
81. Flax HJ. Myofascial pain syndromes - the great mimicker. Bol Asoc Med P R 1995;65:167-70.
82. Schneider MJ. Tender points/fibromyalgia vs. trigger points/myofascial pain syndrome: a need for clarity in terminology and differential diagnosis. Manipulative Physiol Ther 1995;65:398-406.
83. Tschopp KP, Gysin C. Local injection therapy in 107 patients with myofascial pain syndrome of the head and neck. ORL J Otorhinolaryngol Relat Spec 1996;58:306-10.
84. Wreje U, Brorsson B. A multicenter randomized controlled trial of injections of sterile water and saline for chronic myofascial pain syndromes. Pain 1995;65:441-4.
85. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994;59:65-9.
86. Holz RW, Fisher SK. Synaptic transmission and cellular signaling; an overview. In: Siegal GJ, editor. Basic neurochemistry: molecular, cellular, and medical aspects. 6th edition. Philadelphia: Lippincott-Raven Publishers; 1999. p. 191-212 [chapter 10].